Meanwhile, the density of Tregs in all area of tumor tissue in HER2 positive breast cancer patients was also significantly higher (median density, HER2 positive group vs. HER2 negative group=119 vs. 27/mm, p=0.022).However, there was no significant difference in the other subtypes of immune...
Breast cancers are ER-positive, HER2-positive, or triple negative. The type of breast cancer you have determines the type of medication you take. Learn more from experts at WebMD.
然而,近年来,有一批HER2表达水平低(HER2-low)的乳腺癌患者引起了研究者的关注。这部分患者的HER2水平介于HER2阴性和HER2过表达之间,他们的治疗和预后一直不明确。2023年4月,Breast Cancer Research and Treatment杂志发表了一篇题为HER-2 ...
Patritumab deruxtecan (HER3-DXd) is a promising therapy for breast cancer, targeting HER3. Here, the authors analyse the genomic factors that affect the response to HER3-DXd in patients with early-stage HER2-negative breast cancer as part of the SOLTI-1805 TOT-HER3 clinical trial and repo...
在HR+/HER2低表达乳腺癌患者中,T-DXd与标准化疗相比经BICR评估的PFS表现出统计学上显著且具有临床意义的改善(13.2个月 vs 8.1个月,HR=0.62,95%CI 0.51-0.74,P<0.0001)。在ITT人群中,也观察到了统计学上显著且具有临床意义的PFS改善(13.2个月 vs 8.1个月,HR=0.63,95%CI 0.53-0.75,P<0.0001)。
[7] Carlos Barrios, Centro de Pesquisa em Oncologia, Hospital São Lucas, et al. 2024 SABCS P5-05-25 Real world Treatment for HER2 positive HER2 Metastatic Breast Cancer Patients and Compliance to Guideline Recommendations HER2 REAL Brazil Cohort. 2024 SABCS abs#1571 ...
数量的 proteomics 透露在 CD146 促使中的时代介入在乳腺癌细胞中的上皮-mesenchymal 的过渡。 [translate] aClinical Significance of HER2-Positive and Triple-Negative Status in Small (≤ 1 cm) Node-Negative Breast Cancer. HER2正面和三倍消极状态的临床意义在小 (≤ 1 cm) 结消极乳腺癌。 [translate] ...
Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cellsGeradts J., Leek R Harris A L Wilson K S
Currently, the human epidermal growth factor receptor 2 (HER2) status of breast cancer is classified dichotomously as negative or positive to select patients for HER2-targeted therapy. However, with the introduction of novel treatment options, it is important to get more insight in the biology of...
不同HER2 状态下的 pCR 111例(22.1%)患者达到pCR。与HR+乳腺癌患者相比,HR-乳腺癌患者pCR率更高(44%vs4.3%,P<0.0001)。进一步比较HR+和HR-人群中HER2 零表达与HER2低表达的pCR率,发现,HR+乳腺癌患者HER2零表达与HER2 低表达的pC...